Southern Star Research, an Australian CRO specializing in clinical trial acceleration with FDA data compliance, announced at Biotech Showcase its expansion into South Korea to offer clients access to medical and clinical excellence and patients in the region. The Seoul, South Korea office is expected to open next month and the Singapore office to follow. […]
Southern Star Research, an Australian and Asia-Pacific CRO specializing in clinical trial acceleration with FDA data compliance, is taking meetings at Biotech Showcase to discuss the benefits of conducting trials in Australia.
Southern Star Research, Director Corporate Development, Chris Stellatos said this accreditation is a significant development for the company as biotech demand increases for cell and gene therapy trials. It follows a robust assessment process that has taken more than 3 months.
“Supportive rebates, scientific excellence, and rapid approval processes including no requirement for an IND make Australia the stand-out location to conduct clinical trials.”
Southern Star Research, Director Corporate Development, Chris Stellatos said Australia has positioned itself as the most attractive clinical trial destination.
Why Not? The hardest part about placing your clinical trials in Australia is the decision to consider Australia in the first place. Stepping outside a country you know, to one in another timezone? It’s so much easier to stick with where you know.
Reducing Clinical Trial Cost, Complexity & Burden It’s no secret. Clinical trials are getting more complicated and this is driving up the cost of developing new drugs.
Although there are many obstacles that need to be overcome to take an investigational therapeutic successfully through to regulatory approval, the vast majority of issues really come down to two factors – the time and expense associated with clinical trials.
Although pharmacogenetics is a relatively new field of study, it has already made a significant contribution to the standard treatment options for several common cancers.
Starting a phase 1 trial can be exciting and nerve-racking, especially for First Time in Human studies. In most cases, Phase 1 trials are the first opportunity to assess if the properties of a therapeutic, and its safety in humans at increasing doses, behave as predicted.